A recent FDA-approved drug Dupilumab, an antibody targeting to inhibit IL-4 and IL-13, has been adopted to treat severe AD patients; however, nearly 20% subjects experienced adverse events during phase III clinical trials of Dupilumab (Gooderham et al., 2018). This evidence concerns the gene IL13 and Alzheimer disease.